Liang Y, Guo J, Li Z, Liu S, Zhang T, Sun S, Lu F,. A novel method to assess antibody-dependent cell-mediated cytotoxicity against influenza A virus M2 in immunized murine models. Biosaf Health. 2024 Apr 17;6(3):178-185
The matrix protein 2 (M2) is a preferred target for developing a universal vaccine against the influenza A virus (IAV). This study aimed to develop a method for assessing antibody-dependent cell-mediated cytotoxicity (ADCC) associated with M2-based immunization in mice. We first established a stable cell line derived from mouse lymphoma cells (YAC-1) expressing M2 of H3N2. This cell line, designated as YAC-1-M2, was generated using a second-generation lentiviral tricistronic plasmid system to transduce the M2 gene into YAC-1 cells. The ADCC effect induced by polyclonal antibodies targeting matrix protein 2 ectodomain (M2e) was demonstrated by YAC-1-M2 cell lysis by natural killer cells (NK) derived from mice, in the presence of anti-M2 antibodies obtained from mice immunized with an mRNA vaccine based on M2e. This ADCC effect was found to be stronger compared to the effect induced by monoclonal antibodies (14C2) against M2. Moreover, the ADCC effect was enhanced as the effector-to-target ratio of NK to YAC-1-M2 cells increased. In conclusion, we established a novel method to detect ADCC of M2 of IAV, which paves the way for the development of an M2-based universal vaccine against IAV and an in-depth analysis
See Also:
Latest articles in those days:
- [preprint]Mass mortality at penguin mega-colonies due to avian cholera confounds H5N1 HPAIV surveillance in Antarctica 14 hours ago
- [preprint]How the 1918-1920 Influenza Pandemic Spread Across Switzerland - Spatial Patterns and Determinants of Incidence and Mortality 15 hours ago
- Influenza C Virus in Children With Acute Bronchiolitis and Febrile Seizures 19 hours ago
- Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems 19 hours ago
- Avian Influenza Weekly Update # 1026: 12 December 2025 2 days ago
[Go Top] [Close Window]


